Could this Healthcare Stock really climb 135.99% by 2024?

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Lithium Discovery So BIG You Can't Miss it, Even From Space]( [Free Investor Report Reveals Ambitious Plan To Meet Lithium Demand]( --------------------------------------------------------------- November 30, 2023 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [Countries Are Investing Heavily Into Securing Energy Independence]( s a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub. [Learn more about this young company pioneering an incredible potential supply of lithium.]( --------------------------------------------------------------- [Bank Of Montreal]( Symbol: [BMO]( Recent Price: $81.01 Average Analyst Price Target: $93.30 (15.64%) Market Cap: $57.78B Last Year's EPS: $2.16 Consensus EPS Forecast: $2.28 Expected Earnings Date: Dec 01 2023 Recent Analyst Action: Mike Rizvanovic, analyst at KBW, reiterates coverage on [Bank Of Montreal (BMO)]( in the Financial sector with a Buy rating and a price target of $94.48 (6 days ago). [TipRanks.com]( also reports that [Bank Of Montreal]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $93.30 . The target pricing ranges from a high forecast of $99.65 down to a low forecast of $84.89. [Bank Of Montreal (BMO)](’s last closing price was $81.01 which would put the average price target at 15.64% upside. Here are 3rd party ratings for [BMO](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: sell - Zacks.com: Sell, Bottom 33% (167 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Tech insider: "Watch your mailbox"]( You could soon get a strange package from the Federal Government. It's part of the biggest overhaul to our money in decades. And it could change your life (and retirement) in ways that'll surprise you. [Full story.]( --------------------------------------------------------------- [Genesco]( Symbol: [GCO]( Recent Price: $37.24 Average Analyst Price Target: $38.00 (2.04%) Market Cap: $372.32M Last Year's EPS: -$1.59 Consensus EPS Forecast: -$1.23 Expected Earnings Date: Dec 01 2023 Recent Analyst Action: Mitch Kummetz, analyst at Seaport Global, reiterates coverage on [Genesco (GCO)]( in the Consumer Cyclical sector with a Buy rating and a price target of $38 (2 months ago). [TipRanks.com]( also reports that [Genesco]( currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $38.00 . The target pricing ranges from a high forecast of $38 down to a low forecast of $38. [Genesco (GCO)](’s last closing price was $37.24 which would put the average price target at 2.04% upside. Here are 3rd party ratings for [GCO](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Strong Buy, Bottom 44% (141 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- [Tanzanian Royalty Exploration]( Symbol: [TRX]( Recent Price: $0.42 Average Analyst Price Target: $1.30 (213.18%) Market Cap: $108.49M Last Year's EPS: -$0.00018 Consensus EPS Forecast: -$0.00066 Expected Earnings Date: Dec 01 2023 Recent Analyst Action: Heiko Ihle, analyst at H.C. Wainwright, reiterates coverage on [Tanzanian Royalty Exploration (TRX)]( in the Basic Materials sector with a Buy rating and a price target of $1.3 (1 month ago). [TipRanks.com]( also reports that [Tanzanian Royalty Exploration]( currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $1.30 . The target pricing ranges from a high forecast of $1.3 down to a low forecast of $1.3. [Tanzanian Royalty Exploration (TRX)](’s last closing price was $0.42 which would put the average price target at 213.18% upside. Here are 3rd party ratings for [TRX](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Strong Sell, Top 32% (81 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [[BREAKING] New "Living Software" to Revolutionize Warfare]( This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley [Get the name of the company supplying it to the U.S. Army here ]( --------------------------------------------------------------- [OKYO Pharma Limited Sponsored ADR]( Symbol: [OKYO]( Recent Price: $1.70 Average Analyst Price Target: $4.00 (135.99%) Market Cap: $47.00M Last Year's EPS: $0 Consensus EPS Forecast: -$0.11 Expected Earnings Date: Dec 01 2023 Recent Analyst Action: Yi Chen, analyst at H.C. Wainwright, reiterates coverage on [OKYO Pharma Limited Sponsored ADR (OKYO)]( in the Healthcare sector with a Buy rating and a price target of $4 (3 weeks ago). [TipRanks.com]( also reports that [OKYO Pharma Limited Sponsored ADR]( currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $4.00 . The target pricing ranges from a high forecast of $4 down to a low forecast of $4. [OKYO Pharma Limited Sponsored ADR (OKYO)](’s last closing price was $1.70 which would put the average price target at 135.99% upside. Here are 3rd party ratings for [OKYO](: - TipRanks.com: Moderate Buy - TradingView.com: Neutral - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- [Nio]( Symbol: [NIO]( Recent Price: $7.18 Average Analyst Price Target: $15.38 (89.55%) Market Cap: $12.56B Last Year's EPS: -$0.42 Consensus EPS Forecast: -$0.36 Expected Earnings Date: Dec 04 2023 Recent Analyst Action: Tim Hsiao, analyst at Morgan Stanley, reiterates coverage on [Nio (NIO)]( in the Consumer Cyclical sector with a Buy rating and a price target of $18.7 (3 weeks ago). [TipRanks.com]( also reports that [Nio]( currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $15.38 . The target pricing ranges from a high forecast of $8 down to a low forecast of $15. [Nio (NIO)](’s last closing price was $7.18 which would put the average price target at 89.55% upside. Here are 3rd party ratings for [NIO](: - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Buy, Top 15% (37 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Musk: My new robots could be bigger than Tesla]( No one can deny Elon Musk is a visionary. But has he finally gone too far? [>>See the shocking future of AI here<<]( --------------------------------------------------------------- [Gitlab]( Symbol: [GTLB]( Recent Price: $48.60 Average Analyst Price Target: $56.50 (21.03%) Market Cap: $7.22B Last Year's EPS: -$0.06 Consensus EPS Forecast: -$0.03 Expected Earnings Date: Dec 04 2023 Recent Analyst Action: Adam Tindle, analyst at Raymond James, reiterates coverage on [Gitlab (GTLB)]( in the Technology sector with a Hold rating (1 day ago). [TipRanks.com]( also reports that [Gitlab]( currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $56.50 . The target pricing ranges from a high forecast of $65 down to a low forecast of $50. [Gitlab (GTLB)](’s last closing price was $48.60 which would put the average price target at 21.03% upside. Here are 3rd party ratings for [GTLB](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 14% (34 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- [Science Applications]( Symbol: [SAIC]( Recent Price: $115.97 Average Analyst Price Target: $113.80 (-1.87%) Market Cap: $6.16B Last Year's EPS: $2.14 Consensus EPS Forecast: $1.6 Expected Earnings Date: Dec 04 2023 Recent Analyst Action: Cai von, analyst at TD Cowen, reiterates coverage on [Science Applications (SAIC)]( in the Technology sector with a Buy rating and a price target of $120 (2 months ago). [TipRanks.com]( also reports that [Science Applications]( currently has 5 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $113.80 . The target pricing ranges from a high forecast of $120 down to a low forecast of $103. [Science Applications (SAIC)](’s last closing price was $115.97 which would put the average price target at -1.87% upside. Here are 3rd party ratings for [SAIC](: - TipRanks.com: Hold - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 20% (49 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Recent Reports Are A Wake-Up Call For Investors]( the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline. [Meet A Young Company With A Massive Project In Our Backyard - Must See Report]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketTickerPress.com Market Ticker Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. By opening and/or clicking a link containted within this email, you are reconfirming your opt-in status. You can unsubscribe at any time. [If you are not a human, click here.]( MarketTickerPress.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | North Carolina | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software